Medarex

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer

Retrieved on: 
Monday, December 11, 2023
SAN, Business development, Senior, Piers, Patient, Merck & Co., Eli Lilly, Therapy, Recode, BMS, Business, Pharmaceutical industry, Medarex, Genentech

SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.

Key Points: 
  • SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.
  • Piers Ingram, Ph.D., Chief Executive Officer and co-founder of Hummingbird Bioscience said: "We are delighted that Angèle is joining our team.
  • Most recently, she served as Senior Vice President and Head of Business Development at ReCode Therapeutics, where she led business development, corporate development, investor and public relations.
  • I believe Hummingbird Bio's approach to precision medicines and its promising clinical antibody assets will redefine the next generation of precision therapeutics," said Dr. Maki.

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer

Retrieved on: 
Monday, December 11, 2023
SAN, Business development, Senior, Piers, Patient, Merck & Co., Eli Lilly, Therapy, Recode, BMS, Business, Pharmaceutical industry, Medarex, Genentech

SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.

Key Points: 
  • SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.
  • Piers Ingram, Ph.D., Chief Executive Officer and co-founder of Hummingbird Bioscience said: "We are delighted that Angèle is joining our team.
  • Most recently, she served as Senior Vice President and Head of Business Development at ReCode Therapeutics, where she led business development, corporate development, investor and public relations.
  • I believe Hummingbird Bio's approach to precision medicines and its promising clinical antibody assets will redefine the next generation of precision therapeutics," said Dr. Maki.

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Retrieved on: 
Wednesday, July 12, 2023
OMEGA, Chicago Growth Partners, JPMorgan Chase, University, Medarex, Integra, Schade, Strategic planning, Princeton University, Messenger, Bachelor of Arts in Organizational Psychology, Wharton School of the University of Pennsylvania, Business administration, Flagship Pioneering, Widener University Commonwealth Law School, Growth, Master of Business Administration, Merrill (company), Therapy, Management

CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Chris Schade to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Chris Schade to its Board of Directors.
  • Mr. Schade brings over 30 years of experience across the biopharma industry to support the Company’s long-term growth objectives.
  • “We are thrilled to welcome Chris to Omega’s Board of Directors as we advance our pipeline through key milestones in 2023 and beyond,” said Noubar Afeyan, Omega co-founder and Chairman of the Board.
  • He also serves on the board of directors of Sapience Therapeutics, Inc., Integra LifeSciences, Inc., Ring Therapeutics and Alltrna Therapeutics.

MedX Health and PharmaChoice Announce Agreement to Launch MedX Teledermatology Screening Platform Across Canada

Retrieved on: 
Tuesday, April 18, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Global Health Corps, Ontario Basic Income Pilot Project, Pharmacy, Aircraft pilot, Dermatology, Moles, User experience, Spectrophotometry, The Company, Patient, PharmaChoice, Medarex, Medical imaging

Initially, the Pilot Project will be conducted at twenty (20) PharmaChoice locations in four Provinces: British Columbia, Ontario, Nova Scotia and Newfoundland.

Key Points: 
  • Initially, the Pilot Project will be conducted at twenty (20) PharmaChoice locations in four Provinces: British Columbia, Ontario, Nova Scotia and Newfoundland.
  • Depending on assessments, success and demand, the Pilot Project may be expanded up to fifty (50) locations across Canada.
  • Upon successful completion of the Pilot Project, PharmaChoice and MedX anticipate that access to MedX’s teledermatology screening service will be rolled out across the entire PharmaChoice chain of pharmacies.
  • “PharmaChoice Canada is delighted to partner with MedX in bringing its leading teledermatology assessment and screening technology to the communities that we serve,” stated Curtis Chafe, Vice President.

Flagship Pioneering Announces Appointment of Christian Schade as Growth Partner

Retrieved on: 
Tuesday, January 31, 2023
Therapy, Merrill (company), Ecosystem, Health, Schade, Medarex, JPMorgan Chase, Flagship Pioneering, Chicago Growth Partners, Growth, Organization, Aprea-Cuccaro clan, Airline, Management, Flagship

CAMBRIDGE, Mass., Jan. 31, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and biotech leader Christian Schade is joining as Growth Partner.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 31, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and biotech leader Christian Schade is joining as Growth Partner.
  • Schade brings more than thirty years of public and private pharmaceutical and biotechnology industry experience to this role.
  • Schade has served in leadership positions at several companies focused on advancing human health including Novira, Omthera Pharmaceuticals, and Medarex.
  • "I'm thrilled to join Flagship Pioneering and for the opportunity to partner with Flagship's incredible leadership team," said Chris Schade, Growth Partner, Flagship Pioneering.

MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing

Retrieved on: 
Friday, September 9, 2022
Research, Technology, Medical Devices, FDA, Software, Biotechnology, General Health, Health, Science, Other Science, Private placement, Price, Regulation of tobacco by the U.S. Food and Drug Administration, Therapeutic Goods Administration, Closed-end fund, TSX Venture Exchange, Medarex, Physician, Food, Union, Health Canada, TSX, Moles, Funding, Company, Stock exchange, Press release, Global Health Corps, Private, Light, Dermatology, Media release, Security (finance)

No Cash Commissions or Agents Warrants were paid or issued in relation to those seven Convertible Notes.

Key Points: 
  • No Cash Commissions or Agents Warrants were paid or issued in relation to those seven Convertible Notes.
  • Securities issued on are subject to a four month restriction from trading in accordance with relevant regulatory and stock exchange policies.
  • The Company also has further subscriptions in hand for $500,000 which are in process of being funded, and additional subscriptions are anticipated.
  • SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility.

KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, ADHD, SDX, Glycogen storage disease, Ageing, NDA, Endo International, CEO, CNS, GLOBE, Growth, YouTube, Facebook, Benzhydrocodone, Corporate communication, West Virginia University, Niemann–Pick disease, Narcolepsy, Patient, Hydrocodone, Company, Twitter, Acquisition, Central nervous system, NPC, Awareness, Idiopathic hypersomnia, Nasdaq, Medarex, Bristol Myers Squibb, Virginia University, IH, LinkedIn, Paracetamol, Food, KMPH, Pharmaceutical industry, Management

We are very pleased to welcome Nichol to KemPharm and look forward to benefitting from her more than 20 years experience developing investor relations and corporate communications strategies in the biopharmaceutical industry, stated Travis Mickle, Ph.D., President and CEO of KemPharm.

Key Points: 
  • We are very pleased to welcome Nichol to KemPharm and look forward to benefitting from her more than 20 years experience developing investor relations and corporate communications strategies in the biopharmaceutical industry, stated Travis Mickle, Ph.D., President and CEO of KemPharm.
  • Prior to joining KemPharm, Ms. Ochsner served as Executive Vice President of Investor Relations and Corporate Communications with Statera Biopharma.
  • Previously, Ms. Ochsner served as Vice President, Investor Relations and Corporate Communications at TherapeuticsMD.
  • Prior to TherapeuticsMD, she was Executive Director, Investor Relations and Corporate Communications at Aralez Pharmaceutical, and, before that, served as Senior Director, Investor Relations and Corporate Communications at Auxilum until its acquisition by Endo International plc for $2.6 billion.

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

Retrieved on: 
Thursday, July 7, 2022
Patient, Carmine, Achondroplasia, CEO, Medarex, B cell, Novartis, Pulmonology, Physiology, BMS, Amoxicillin/clavulanic acid, Bay, BioMarin Pharmaceutical, Nobel Prize, Senior advisor, Formoterol, SA, BMN, Nobel Prize in Physiology or Medicine, CMO, MBA, Non-executive director, GlaxoSmithKline, SVP, Bristol Myers Squibb, Haemophilia, EVP, Physician, Royal Australasian College, Royal college, Sangamo Therapeutics, VP, Board, Multiple myeloma, Drug development, Batten disease, Lymphatic system, Pharmaceutical industry, Pegvaliase, Medicine, Omalizumab, Phenylketonuria

Bryce Carmine, HaemaLogiX's Chairman and CEO commented: "Geoff's impressive, globally recognised background in drug development, and in particular, in antibody development, makes him a valuable contribution to the HaemaLogiX board.

Key Points: 
  • Bryce Carmine, HaemaLogiX's Chairman and CEO commented: "Geoff's impressive, globally recognised background in drug development, and in particular, in antibody development, makes him a valuable contribution to the HaemaLogiX board.
  • Importantly, during his time at Medarex, Geoff oversaw the preclinical and clinical development of KappaMab, our multiple myeloma drug candidate.
  • He brings outstanding industry knowledge and a highly translatable skillset to our Board mix.
  • Dr. Nichol brings nearly 30 years' experience in drug development.

MedX Announces Final Acceptance of Issuance of Series II Convertible Loan Notes

Retrieved on: 
Tuesday, June 21, 2022
Software, Research, General Health, Telemedicine, Virtual Medicine, Technology, Genetics, Science, Biotechnology, FDA, Telecommunications, Other Science, Health, Therapeutic Goods Administration, TSX, Union, Moles, Regulation of tobacco by the U.S. Food and Drug Administration, Note, Notice, Global Health Corps, Company, Health Canada, Media release, Finance Secretary (India), Exercise, Physician, Medarex, Indian stock exchange, Light, Dermatology, Food, TSX Venture Exchange, Series, Security (finance), Holder

MedX Health Corp. (MedX or the Company) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it has received final Acceptance from the TSX Venture Exchange in respect of the Closing of the placement of Series II Convertible Notes that took place on March 21, 2022, and which comprised issuance of 20 Series II Convertible Notes, and raised a total of $1 Million.

Key Points: 
  • MedX Health Corp. (MedX or the Company) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that it has received final Acceptance from the TSX Venture Exchange in respect of the Closing of the placement of Series II Convertible Notes that took place on March 21, 2022, and which comprised issuance of 20 Series II Convertible Notes, and raised a total of $1 Million.
  • The Series II Convertible Notes bear interest at 8% per year, payable Half-yearly, and will mature on December 31, 2026 (the Maturity Date).
  • The Series II Convertible Notes may be converted, at the option of the Holder, into units at $0.10 per unit (Series II Unit) at any time until the Maturity Date.
  • Each Series II Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Series II Share Purchase Warrant.

MedX Health Adds New Board Member

Retrieved on: 
Tuesday, June 14, 2022
Health, Medical Devices, Technology, Telemedicine, Virtual Medicine, Health Technology, Telecommunications, Biotechnology, United Kingdom, Moles, Company, Pharmacy, Board of directors, Therapeutic Goods Administration, Telehealth, Spectrophotometry, Johnson & Johnson, Skin cancer, TSX Venture Exchange, Food, Gulf Cooperation Council, Medtronic, Aesthetics, CEO, Partnership, Brisbane Diamantina Health Partners, Dermatology, Physician, Medarex, Growth, Health Canada, Technology, Economics, Adoption, TSX, Emirates, Diagnosis, Union, Media release, United Arab Emirates, Board, Global Health Corps, Light, Regulation of tobacco by the U.S. Food and Drug Administration, Management, Pharmaceutical industry, Medical device

MedX Health Corp. (MedX or the Company) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Naman Demaghlatrous has been appointed to its Board of Directors.

Key Points: 
  • MedX Health Corp. (MedX or the Company) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Naman Demaghlatrous has been appointed to its Board of Directors.
  • The partnership with Health Partners in the United Kingdom, currently conducting its pilot program, represents the Companys first foray into the occupational health vertical.
  • MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology.
  • SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility.